Key Takeaways
Extended Takeaways
- Baseline sexual dysfunction was common despite ongoing antidepressant therapy, affecting 82.5% of the overall sample, including 85.0% of women and 76.7% of men; this supports routine sexual-function assessment in patients with major depressive disorder who report inadequate antidepressant response.
- The sexual-function benefit was clinically meaningful at 6 weeks, with a CSFQ-14 Total score LSMD of 2.7 vs placebo +ADT (ES, 0.38; P <.0001), which falls within the article’s cited 2- or 3-point threshold for meaningful change.
- Among patients with sexual dysfunction at baseline, adjunctive lumateperone was associated with more recovery to normal sexual function than placebo +ADT (26.3% vs 15.2%), while in those with normal baseline sexual functioning, rates of retained normal function were identical at 74.4% in both groups.
- Women showed the clearest signal for benefit, with CSFQ-14 Total score improvement of LSMD, 3.5; ES, 0.47; P <.0001 overall and LSMD, 3.8; ES, 0.50; P<.0001 in women with baseline sexual dysfunction, whereas results in men were numerically favorable but not statistically significant.
- Sexual-function gains were broad rather than limited to a single domain, with significant improvements in pleasure, desire/frequency, desire/interest, arousal/excitement, and orgasm/completion, suggesting clinicians may see changes across desire, arousal, and orgasmic function rather than only reduced sexual adverse effects.
- Most of the sexual-function signal appeared tied to mood improvement: change in CSFQ-14 Total score correlated with MADRS change at Day 22 (r =−0.262) and Day 43 (r =−0.378), and approximately 66.2% of the treatment effect on CSFQ-14 Total score was mediated through changes in MADRS Total score.
